A Phase 1b, Open-Label, Multiple-Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of NBI-98854 in Children and Adolescents With Tourette Syndrome

Trial Profile

A Phase 1b, Open-Label, Multiple-Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of NBI-98854 in Children and Adolescents With Tourette Syndrome

Completed
Phase of Trial: Phase I

Latest Information Update: 30 Jan 2016

At a glance

  • Drugs Valbenazine (Primary)
  • Indications Gilles de la Tourette's syndrome
  • Focus Adverse reactions; Pharmacokinetics
  • Acronyms T-FORCE
  • Sponsors Neurocrine Biosciences
  • Most Recent Events

    • 16 Dec 2015 Results published in a Neurocrine Biosciences media release.
    • 16 Dec 2015 Status changed from recruiting to completed, according to a Neurocrine Biosciences media release.
    • 20 Oct 2015 According to a Neurocrine Biosciences media release, the company expects to file an NDA for valbenazine [NBI-98854] for the treatment of tardive dyskinesia in 2016.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top